Literature DB >> 33656465

Schizophrenia during pregnancy.

Paola Dazzan1.   

Abstract

PURPOSE OF REVIEW: A diagnosis of schizophrenia has significant implications for women of childbearing age, pregnant or considering a pregnancy, ranging from sexual health, psychopharmacological treatment, to the occurrence of negative pregnancy and foetal outcomes. We provide a short narrative review of recent papers focusing on these issues. RECENT
FINDINGS: Although pregnancy rates have been increasing in women with a diagnosis of schizophrenia, they also tend to have altogether fewer pregnancies and fewer live births than women without this diagnosis, and also higher rates of induced abortions.Use of antipsychotics in pregnancy has also increased, and evidence suggests lack of significant contraindications for their use in this period. However, drug levels monitoring may be recommended across the three trimesters, as levels may change in relation to pregnancy-related physiology.Monitoring of physical health is an increasingly crucial issue, given higher risk of gestational diabetes, negative obstetric and infant outcomes in these women.
SUMMARY: There is an urgent need to generate valid and reproducible research that could help implement appropriate treatment protocols and relapse-prevention approaches, and interventions based on strong pharmaceutical targets for the benefit of pregnant women with a diagnosis of schizophrenia, their families and their children.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33656465     DOI: 10.1097/YCO.0000000000000706

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.787


  2 in total

1.  Antipsychotic utilization patterns in pregnant women with psychotic disorders: a 16-year population-based cohort study.

Authors:  Jenny Wai Yiu Law; Joe Kwun Nam Chan; Corine Sau Man Wong; Eric Yu Hai Chen; Wing Chung Chang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-06       Impact factor: 5.270

Review 2.  Antipsychotic medication for women with schizophrenia spectrum disorders.

Authors:  Bodyl A Brand; Yudith R A Haveman; Franciska de Beer; Janna N de Boer; Paola Dazzan; Iris E C Sommer
Journal:  Psychol Med       Date:  2021-11-12       Impact factor: 10.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.